These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 33060766)
1. Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient. Osumi H; Muroi A; Sakahara M; Kawachi H; Okamoto T; Natsume Y; Yamanaka H; Takano H; Kusama D; Shinozaki E; Ooki A; Yamaguchi K; Ueno M; Takeuchi K; Noda T; Nagayama S; Koshikawa N; Yao R Sci Rep; 2020 Oct; 10(1):17455. PubMed ID: 33060766 [TBL] [Abstract][Full Text] [Related]
2. Crenolanib Regulates ERK and AKT/mTOR Signaling Pathways in RAS/BRAF-Mutated Colorectal Cancer Cells and Organoids. Fujino S; Miyoshi N; Ito A; Yasui M; Ohue M; Ogino T; Takahashi H; Uemura M; Matsuda C; Mizushima T; Doki Y; Eguchi H Mol Cancer Res; 2021 May; 19(5):812-822. PubMed ID: 33579816 [TBL] [Abstract][Full Text] [Related]
3. Early response in phosphorylation of ribosomal protein S6 is associated with sensitivity to trametinib in colorectal cancer cells. Hirashita Y; Tsukamoto Y; Kudo Y; Kakisako D; Kurogi S; Hijiya N; Nakada C; Uchida T; Hirashita T; Hiratsuka T; Akagi T; Ueda Y; Shiroshita H; Etoh T; Mizukami K; Honda K; Okimoto T; Kodama M; Inomata M; Moriyama M; Murakami K Lab Invest; 2021 Aug; 101(8):1036-1047. PubMed ID: 33911189 [TBL] [Abstract][Full Text] [Related]
4. Relationships among Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081 [TBL] [Abstract][Full Text] [Related]
5. IFN/STAT signaling controls tumorigenesis and the drug response in colorectal cancer. Sakahara M; Okamoto T; Oyanagi J; Takano H; Natsume Y; Yamanaka H; Kusama D; Fusejima M; Tanaka N; Mori S; Kawachi H; Ueno M; Sakai Y; Noda T; Nagayama S; Yao R Cancer Sci; 2019 Apr; 110(4):1293-1305. PubMed ID: 30724425 [TBL] [Abstract][Full Text] [Related]
6. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829 [TBL] [Abstract][Full Text] [Related]
7. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling. Ponsioen B; Post JB; Buissant des Amorie JR; Laskaris D; van Ineveld RL; Kersten S; Bertotti A; Sassi F; Sipieter F; Cappe B; Mertens S; Verlaan-Klink I; Boj SF; Vries RGJ; Rehmann H; Vandenabeele P; Riquet FB; Trusolino L; Bos JL; Snippert HJG Nat Cell Biol; 2021 Apr; 23(4):377-390. PubMed ID: 33795873 [TBL] [Abstract][Full Text] [Related]
8. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322 [TBL] [Abstract][Full Text] [Related]
9. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. Verissimo CS; Overmeer RM; Ponsioen B; Drost J; Mertens S; Verlaan-Klink I; Gerwen BV; van der Ven M; Wetering MV; Egan DA; Bernards R; Clevers H; Bos JL; Snippert HJ Elife; 2016 Nov; 5():. PubMed ID: 27845624 [TBL] [Abstract][Full Text] [Related]
10. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910 [TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911 [TBL] [Abstract][Full Text] [Related]
13. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers. Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755 [TBL] [Abstract][Full Text] [Related]
15. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150 [TBL] [Abstract][Full Text] [Related]
16. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900 [TBL] [Abstract][Full Text] [Related]
17. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells. Song Q; Sun X; Guo H; Yu Q Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807 [TBL] [Abstract][Full Text] [Related]
18. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells. Ambrosini G; Khanin R; Carvajal RD; Schwartz GK Mol Cancer Ther; 2014 Aug; 13(8):2073-80. PubMed ID: 24899684 [TBL] [Abstract][Full Text] [Related]
20. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies. Kuracha MR; Thomas P; Loggie BW; Govindarajan V PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]